Key Developments: Sanofi SA (SNY)

SNY on New York Consolidated

51.75USD
24 Apr 2015
Change (% chg)

-- (--)
Prev Close
$51.75
Open
--
Day's High
--
Day's Low
--
Volume
50
Avg. Vol
1,625,987
52-wk High
$57.42
52-wk Low
$43.57

Search Stocks

Latest Key Developments (Source: Significant Developments)

Sanofi partnership with Ypsomed Group to include new project
Thursday, 23 Apr 2015 08:00pm EDT 

Ypsomed:Says the long-standing partnership between Sanofi and Ypsomed Group will be bolstered by new major project.New major project to start in late 2016.Ypsomed plans to manufacture components for injection systems on additional dedicated production line.Additional annual capacity to be in double-digit millions.  Full Article

Innate Pharma and Sanofi collaborate on antibody-drug conjugates
Thursday, 16 Apr 2015 01:30am EDT 

Innate Pharma SA:Innate Pharma and Sanofi collaborate on next generation antibody-drug conjugates.Innate Pharma has entered into a collaboration agreement with Sanofi to apply Innate Pharma's site-specific conjugation technology to development of new antibody drug conjugates.  Full Article

Sanofi's Sanofi Pasteur division's Gardasil 9 HPV vaccine gets positive opinion from EMA
Friday, 27 Mar 2015 09:02am EDT 

Sanofi SA:Says Gardasil 9, new HPV vaccine from Sanofi Pasteur MSD granted positive opinion by European Ccommittee for Medicinal Products for Human Use.Says European Medicines Agency (EMA) has adopted this week positive opinion recommending marketing authorisation for Gardasil 9, a 9-valent HPV vaccine.  Full Article

Sanofi SA's Sanofi Pasteur division announces FDA approval of Quadracel DTaP-IPV vaccine
Wednesday, 25 Mar 2015 12:15pm EDT 

Sanofi SA:Sanofi Pasteur, vaccines division of Sanofi, says that FDA has approved use of Quadracel vaccine for active immunization against diphtheria, tetanus, pertussis and poliomyelitis in children 4 through 6 years of age.FDA approval is based on data from pivotal multicenter, randomized, controlled, phase III study designed to compare safety and immunogenicity of Quadracel vaccine with DAPTACEL and IPOL vaccines.  Full Article

Evotec AG and Sanofi SA sign definitive agreement for major multi-component strategic alliance
Thursday, 19 Mar 2015 08:11pm EDT 

Evotec AG:Says that definitive agreement for major multi-component strategic alliance over next five years has been signed with Sanofi SA.Transaction is expected to close on March 31.Says that this successfully concludes exclusive negotiations for major multi-component strategic collaboration which two companies entered into on Dec. 2.Collaboration will result in minimum guaranteed commitment from Sanofi to Evotec of 250 million euros, including more than 40 million euros upfront cash payment.Five-year agreement includes initiatives with both of Evotec's two business segments (EVT Execute and EVT Innovate).  Full Article

Sanofi SA announces top-line results for cardiovascular outcomes study of Lyxumia (lixisenatide)
Thursday, 19 Mar 2015 02:11am EDT 

Sanofi SA:Announced top-line results of phase IIIb ELIXA cardiovascular outcomes study, which compared lixisenatide to placebo in high-risk population of adults with type 2 diabetes evaluating cardiovascular safety.Study showed that lixisenatide was non-inferior, although not superior, to placebo for cardiovascular safety.Lixisenatide is once-daily prandial glucagon-like peptide-1 receptor agonist (GLP-1 RA) for treatment of adult patients with type 2 diabetes mellitus.GLP-1 is naturally-occurring peptide hormone that is released within minutes after eating meal.  Full Article

Sanofi affiliate Shantha to provide up to 37 million doses of Shan5
Tuesday, 17 Mar 2015 02:00am EDT 

Sanofi SA:Said Shantha to provide up to 37 million doses of Shan5.Announced its affiliate Shantha Biotechnics, located in India, has delivered first 400,000 doses of its pediatric pentavalent vaccine Shan5 to support immunization of children in India.  Full Article

Sanofi and Regeneron announce 18-month results of ODYSSEY long term trial with praluent (alirocumab)
Saturday, 14 Mar 2015 10:58pm EDT 

Sanofi SA:Announced the 18-month results of a Phase 3 long term trial with praluent (alirocumab) with Regeneron Pharmaceuticals.In the ODYSSEY LONG TERM trial, Praluent 150 mg every two weeks reduced low-density lipoprotein cholesterol by an additional 62 percent at week 24 when compared to placebo, the primary efficacy endpoint of the study, with consistent LDL-C lowering maintained over 78 weeks.  Full Article

Sanofi SA receives FDA approval of once-daily basal insulin Toujeo
Wednesday, 25 Feb 2015 08:25pm EST 

Sanofi SA:Announced that the U.S. Food and Drug Administration (FDA) approved Toujeo (insulin glargine injection, 300 U/mL), a once-daily long-acting basal insulin, to improve glycemic control in adults living with type 1 and type 2 diabetes.Toujeo is expected to be available in the U.S. at the beginning of Q2 2015.  Full Article

Sanofi SA under fire in France over new CEO's pay package - Reuters
Monday, 23 Feb 2015 05:40am EST 

Sanofi SA:Came under fire from French government ministers on Feb. 23 over a welcome bonus planned for its new CEO - Reuters.Sanofi's new boss, Olivier Brandicourt, could pocket a one-off golden handshake of 4 mln euros ($4.5 mln) in addition to making 4.2 mln euros a year.The company said that the former medical doctor would be paid a fixed salary of 1.2 mln euros a year plus, a performance-related amount targeted at 150 pct of that with a cap at 250 pct.He would also get stock options and performance shares.His 4 mln euros golden handshake on top of that was billed as compensation for loss of benefits at his former employer Bayer, and will be split between 2 mln when he starts in April and the rest in January 2016 if he is still in the job.  Full Article

BRIEF-Ypsomed to increase production capacity for new project with Sanofi

* Long-standing partnership between the French pharmaceutical group Sanofi and the Ypsomed Group will be bolstered by new major project

Search Stocks